14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 09, 2026
DAWN vs ACHV: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
DAWN Captures Overall Composite Edge (58.3 HOLD vs 56.6 HOLD), While ACHV Leads 3–2 on Growth & Valuation Pillars
DAWN Overall Winner
6-Pillar Tally: DAWN 2 – 3 ACHV (1 Tie)
Matrix Metrics: DAWN 6 – 4 ACHV
As of Nov 09, 2026, Day One Biopharmaceuticals, Inc. (DAWN) captures the overall head-to-head institutional edge over Achieve Life Sciences, Inc. (ACHV) on higher Unified Composite conviction (58.3/100 HOLD vs. 56.6/100 HOLD) after splitting the core matrix 6–4 (led by Growth & Scale, Options & Positioning), while ACHV wins 3–2 across the 6-pillar growth and valuation breakdown. DAWN trades at $21.53 (N/M Forward P/E, -51.1% operating margin) versus ACHV at $6.78 (35.3x Forward P/E, 0.0% operating margin).
Growth vs. Quality Trade-Off: DAWN earns the overall head-to-head edge with a stronger Unified Composite Score (58.3/100 HOLD vs. ACHV 56.6/100 HOLD) and 0.03β · 2% Vol risk profile, whereas ACHV leads top-line expansion (+0.0% YoY revenue growth, 17.68x PEG, and 3 of 6 institutional pillars) for higher-beta growth mandates.
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on DAWN vs ACHV. Trailing 12-month operating profitability (DAWN -51.1% vs ACHV 0.0%) and valuation multiples (DAWN N/M vs ACHV 35.3x Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Biotechnology value chain with $692.8M market capitalization and 0.0% operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
Investor FAQ DAWN vs ACHV Key Questions & Quantitative Answers
As of Nov 09, 2026, Day One Biopharmaceuticals, Inc. (DAWN) captures the overall head-to-head institutional edge over Achieve Life Sciences, Inc. (ACHV) on higher Unified Composite conviction (58.3/100 HOLD vs. 56.6/100 HOLD) after splitting the core matrix 6–4 (led by Growth & Scale, Options & Positioning), while ACHV wins 3–2 across the 6-pillar growth and valuation breakdown. DAWN trades at $21.53 (N/M Forward P/E, -51.1% operating margin) versus ACHV at $6.78 (35.3x Forward P/E, 0.0% operating margin). Growth vs. Quality Trade-Off: DAWN earns the overall head-to-head edge with a stronger Unified Composite Score (58.3/100 HOLD vs. ACHV 56.6/100 HOLD) and 0.03β · 2% Vol risk profile, whereas ACHV leads top-line expansion (+0.0% YoY revenue growth, 17.68x PEG, and 3 of 6 institutional pillars) for higher-beta growth mandates.
DAWN leads the Growth & Scale pillar: DAWN posts +83.9% YoY revenue growth and +0.0% YoY earnings growth on $158M TTM revenue (89.1% gross margin, -51.1% operating margin), compared with ACHV at +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). On trailing 12-month operating scale, DAWN generates $158M in USD-normalized revenue versus N/A for ACHV. In operating R&D and SG&A reinvestment, DAWN deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for ACHV.
ACHV screens cheaper on headline valuation multiples. DAWN trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 14.0x EV/Revenue (-78.6% EBITDA margin), whereas ACHV trades at 35.3x Forward P/E, 35.3x Trailing P/E, 17.68x PEG, and N/M EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against DAWN (-22.7% ROE) versus ACHV (-845.0% ROE) capital efficiency.
In options market volatility and institutional positioning, DAWN carries 0.6% implied volatility (<1st %ile, Compressed (<25th %ile)), a 0.45x (Call-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.03β · 2% Vol realized risk). By comparison, ACHV carries 88.3% implied volatility (23rd %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in a BREAKOUT options structure phase (1.73β · 62% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 09, 2026. For educational research only; not investment advice.